Gastrointestinal Disorder (misc) - BioSpace offers Pharmaceutical ...
Lexicon Pharmaceuticals, Inc. (LEXG)'s Drug Candidate for Carcinoid ..... Inc. ( BPA) Signs License Option Agreement With European Pharmaceutical Company; ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...
|
FACT SHEET
Teva is one of the leading pharmaceutical companies in the world. ... Expands Teva's leadership position in European generics – markets, .... Acromegaly; tx
of diarrhea assoc w/ carcinoid tumors and vasoactive intestinal peptide tumors
...
http://www.teva.co.il/pdf/factsheet200602.pdf...
|
{1} Submits New Drug Application To {2} For Sanvar IR - News ...
"I am very pleased that H3 Pharma has become one of the few companies in Quebec to ... We are now in active discussions with a number of pharmaceutical
companies to conclude ... in the key world markets of the Americas and Europe
this year. ... the management of life-long symptoms of carcinoid tumors and
acromegaly ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1532612...
|
Molecular Insight Pharmaceuticals Finalizes Onalta(TM ...
21 Oct 2009 ... Upon European Medicines Agency (EMEA) approval of a Market Authorization ... Onalta(TM) is being developed for the treatment of carcinoid and other ...
competition from other pharmaceutical or biotechnology companies; ...
http://biz.yahoo.com/iw/091021/0549623.html?.v=1...
|
Patient Group Support - Ipsen, an innovation driven international ...
... by the European Federation of Pharmaceutical Industries and Associations ... Onkologischer Arbeitskreis Klinikum Mannheim; Carcinoid Call Point GmbH, ...
http://www.ipsen.com/?page=ethics&content=patient_group_supp...
|
Heart attack/Myocardial infarction - Biotech, Clinical Research ...
Biotech and Pharmaceutical News & Jobs. Search the Site ... Eli Lilly and Company (LLY): Multiple Types of Heart Attacks Reduced by Prasugrel in ...
Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor
Society ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...
|
Lexicon Pharmaceuticals - Wikipedia, the free encyclopedia
Alan J. Main, Ph.D., EVP of Pharmaceutical Research ... The company's original name was Lexicon Genetics, Inc. but in 2007, they changed their .... Orphan Drug
Designation from the European Medicines Agency (EMEA) for LX1032. ... Lexicon
initiated a Phase 2 study in patients with carcinoid syndrome in July 2009. ...
http://en.wikipedia.org/wiki/Lexicon_Pharmaceuticals...
|
Pharmaceuticals
with carcinoid tumors and other types of gastrointestinal neuro- ... opinion for a liquid formulation for European approval and filed ..... in the development of
new pharmaceutical products; unexpected clinical ... All product names appearing
in italics are trademarks licensed to or owned by Novartis Group companies.
http://www.novartis.com/downloads/newsroom/corporate-press-k...
|
{2} Drug Sandostatin LAR Approved In Japan For Acromegaly And ...
In the western Phase III clinical trials for malignant carcinoid syndrome, ... Headquartered in Basel, Switzerland, Novartis Group companies employ about ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1585832...
|
Neuropharmacology of 5-hydroxytryptamine
Major players in the U.K. were Glaxo, Beecham and Wellcome (all then different companies of course) and Sandoz and Merrell Dow in Europe. ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1760750/...
|
